Capsules, Softgels, Oral Powders and Other Formulations

Quick answer

Capsules, softgels, powders and "water-soluble" or "nano" products are swallowed cannabinoid forms with no flavor or candy appearance. The main scientific issue is absorption: CBD taken by mouth is absorbed poorly and unevenly, and the formulation and food eaten with it change how much reaches the blood. [1] That means the milligrams on two different products are not directly comparable. This page gives no preparation, dosing or buying advice.

Evidence labels used: approved medicine, promising but limited, mixed, insufficient evidence, marketing claim, and "Proper evidence not found".

What these forms are

• Capsules and softgels. A shell holding a cannabinoid powder or oil. A review of CBD in dietary supplements lists oils, capsules, gummies and e-liquids as the main supplement forms. [1]
• Oral powders. Dry products, sometimes made from an emulsion, that are swallowed or mixed into a drink.
• "Water-soluble," "nano," "enhanced" or "bioavailable." These are terms makers use for formulations meant to improve absorption. They are not regulatory categories. Treat them as marketing claims unless a study of that exact product shows otherwise.

For oils and tinctures, see CBD Products: Oils, Topicals, Edibles and Labels.

What absorption studies found

All studies below are small, short, single-dose trials in healthy volunteers. Amounts are what the studies used, not recommendations, and results do not tell you whether a product helps any condition.

A 2026 formulation paper describes oral CBD bioavailability as roughly 6%, because of low solubility and first-pass metabolism, which is why makers pursue new formulations. [5] That paper's own test results were in rats, so they are preclinical (cells/animals only) and should not be applied to people.

Why it matters. More absorption means more exposure from the same label milligrams. Risks that scale with exposure, such as liver injury and drug interactions, were identified by the FDA for CBD. [6]

Evidence for health benefit

• Approved medicine. The FDA-approved CBD product is a prescription oral medicine for seizures linked to Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex; the FDA has approved no other CBD products. [6] Results from it do not transfer to consumer capsules or powders. See Approved Cannabinoid Medicines.
• Other conditions. A 2018 review of two studies found that CBD capsules did not change clinical remission in active ulcerative colitis versus placebo, with more side effects. [7] That is insufficient evidence for any use.
• Label accuracy of capsules. We found testing of tinctures, gummies, vapes and topicals, but no independent label-accuracy study of capsules or powders: Proper evidence not found. [8]

"Nano" and safety

In 2026 the European Food Safety Authority concluded that safety could not be established for one CBD isolate, citing uncertainty about the formulations the applicant intended to market, including possible nanoparticles. [9] A different 2026 opinion on synthetic CBD in MCT oil judged it safe at a stated maximum intake except for people taking medication, for whom safety could not be established. [10]

Who should be careful

Pregnancy, children, and anyone taking medicine should read CBD-Medication Interactions and talk to a prescriber. The FDA notes CBD can raise or lower the effects of other medicines. [6]